Clinical Trial Update: Study of 1.25 mmol/L Calcium Dialysate on Mineral Metabolism in Haemodialysis Patients. [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating calcium dialysate at 1.25 mmol/L for mineral metabolism in haemodialysis patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercalcemia
• Hyperparathyroidism

Drugs mentioned

• Calcium dialysate 1.25 mmol/L (calcium dialysate)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hyperparathyroidism, Hypercalcemia | Phase 2 | Status: COMPLETED